Company Overview and News

 
YTL PowerSeraya rolls out integrated brand for business and consumer energy

2018-10-03 businesstimes.com.sg
YTL PowerSeraya (YTLPS) has launched an integrated brand for its business and consumer energy portfolio known as Geneco, ahead of the nationwide rollout of the Energy Market Authority's (EMA) open electricity market on Nov 1.
YTLPF 6742

 
YTL Power downgraded to hold at Affin Hwang; price target RM1.10

2018-10-02 theedgemarkets
KUALA LUMPUR (Oct 2): Affin Hwang Investment Bank Bhd analyst Ng Chi Hoong downgraded the recommendation on YTL Power International Bhd to hold from buy.
YTLPF 6742

 
TNB installed 13,000MW of power generation capacity since 1949

2018-09-18 theedgemarkets
KUALA LUMPUR (Sept 18): Tenaga Nasional Bhd (TNB) has installed over 13,000 megawatts (MW) of power generation capacity in Peninsular Malaysia since 1949, when there were only 40 MW.
5347 YTLPF TNABY 6742 TNABF

 
Econpile, Destini, Sentoria, Dayang Enterprise, Telekom Malaysia, Bumi Armada, CIMB, Taliworks, YTL Corp, Pos Malaysia, Genting Malaysia, UMW Holdings, PPB Group, Boustead Holdings and 7-Eleven

2018-08-29 theedgemarkets
KUALA LUMPUR (Aug 29): Based on corporate announcements and news flow today, stocks in focus on Monday (Aug 30) may include Econpile Holdings Bhd, Destini Bhd, Sentoria Group Bhd, Dayang Enterprise Holdings Bhd, Telekom Malaysia Bhd, Bumi Armada Bhd, CIMB Group Holdings Bhd, Taliworks Corp Bhd, YTL Corp Bhd, Pos Malaysia Bhd, Genting Malaysia Bhd, UMW Holdings Bhd, PPB Group Bhd, Boustead Holdings Bhd and 7-Eleven Malaysia Holdings Bhd.
BSTHY WLMIF BRDBF GMALF 4065 5253 5141 6742 5213 2771 CIMDF 5210 4634 GMALY WLMIY 1023 4588 4863 4715 YTLPF MYTEF BSMAF F34 1818

 
YTL Power FY18 net profit falls to RM716.88m

2018-08-29 malaymail
KUALA LUMPUR, Aug 29 — YTL Power International Bhd’s net profit for the financial year ended June 30, 2018 (FY18) fell 8.9 per cent to RM716.88 million from RM787.77 million registered last year.
YTLPF 6742 BSMAF 1818

 
YTL Corp reports 4Q net loss, declares 4 sen dividend

2018-08-29 theedgemarkets
KUALA LUMPUR (Aug 29): YTL Corp Bhd fell into the red in the fourth quarter ended June 30, 2018 (4QFY18), posting a net loss of RM43.36 million versus a net profit of RM229.33 million in the same period last year, mainly due to higher losses from the management services and others division.
YTLPF 6742

 
Gamuda, KPS, Bumi Armada, SLP Resources, Frontken, Axiata, Anzo, Lay Hong, AHP, Parlo, Nylex, Ancom, YTL Power, UEM Sunrise and T7 Global

2018-08-03 theedgemarkets
KUALA LUMPUR (Aug 3): Based on corporate announcements and news flow today, stocks in focus on Monday (Aug 6) may include: Gamuda Bhd, Kumpulan Perangsang Selangor Bhd, Bumi Armada Bhd, SLP Resources Bhd, Frontken Corp Bhd, Axiata Bhd, Anzo Holdings Bhd, Lay Hong Bhd, Amanah Harta Tanah PNB, Parlo Bhd, Nylex (Malaysia) Bhd, Ancom Bhd, YTL Power International Bhd, UEM Sunrise Bhd and T7 Global Bhd.
9385 BRDBF U96 HYFXY 7248 6742 9342 SCRPY 5210 5843 4952 5148 YTLPF HYFXF SCRPF

1
Sembcorp, YTL said to eye pursuing US$1.1b Hyflux plant

2018-08-03 theedgemarkets - 1
SINGAPORE (Aug 3): Sembcorp Industries Ltd and Keppel Corp are among parties planning to study bids for Hyflux Ltd’s biggest asset, according to people with knowledge of the matter, in a sale that’s key to helping the cash-strapped company get back on its feet.
MLYBY MPCIY MLYNF U96 HYFXY 6742 SCRPY 1155 YTLPF MPI MPCFF HYFXF SCRPF

 
Hyflux sets Aug 3 deadline for 22 potential rescue financiers to indicate interest

2018-08-03 channelnewsasia
SINGAPORE: Troubled water treatment firm Hyflux has signed non-disclosure agreements with 22 potential rescue financiers, who have until Friday (Aug 3) to submit their expressions of interests.
YTLPF U96 6742 SCRPF SCRPY

 
Sembcorp, YTL Said to Eye Pursuing $1.1 Billion Hyflux Plant - Bloomberg

2018-08-03 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
MLYBY MPCIY MLYNF U96 HYFXY 6742 SCRPY 1155 YTLPF MPI MPCFF HYFXF SCRPF

 
Sembcorp, YTL to consider pursuing US$1.1bil Hyflux plant

2018-08-03 thestar.com.my
Officials from Hyflux, a Singapore-based water treatment company, guide Prime Minister Lee Hsien Loong, center, during the official opening of the country's first desalination plant in Singapore Tuesday, Sept. 13, 2005. - AP filepic
MLYBY MPCIY MLYNF U96 HYFXY 6742 SCRPY 1155 YTLPF MPI MPCFF HYFXF SCRPF

 
Sembcorp, YTL said to mull pursuing US$1.1b Hyflux plant

2018-08-02 theedgemarkets
SINGAPORE (Aug 2): Sembcorp Industries Ltd and Keppel Corp are among parties planning to study bids for Hyflux Ltd’s biggest asset, according to people with knowledge of the matter, in a sale that’s key to helping the cash-strapped company get back on its feet.
MLYBY MPCIY MLYNF U96 HYFXY 6742 SCRPY 1155 YTLPF MPI MPCFF HYFXF SCRPF

1
PLUS and IHH Healthcare likely to be key priorities for fund

2018-07-28 thestar.com.my - 1
Major shareholder: Traffic is seen on the North-South Expressway. PLUS Malaysia Bhd is jointly owned by UEM Group Bhd, a wholly owned subsidiary of Khazanah, and the Employees Provident Fund.
5225 FORTIS YTLPF 6742 Q0F IHHHF 532843

 
Policy reviews unlikely to affect TNB, YTL Power

2018-07-26 theedgemarkets
Power sector Maintain overweight: We believe Tenaga Nasional Bhd (TNB) and YTL Power International Bhd will not be affected by the recent change of government and ongoing policy review exercises. We maintain “buy” on TNB with an unchanged target price (TP) of RM17.50, on stable earnings and cash flow with new contribution from Jimah East (2019) and SIPP (2020). We also maintain “buy” on YTL Power with a higher TP of RM1.
5347 YTLPF TNABY 6742 TNABF

 
Tenaga and YTL Power will not be affected by recent change of government and ongoing policy review exercises, says HLIB Research

2018-07-25 theedgemarkets
KUALA LUMPUR (July 25): Hong Leong IB Research has maintained its “Overweight” rating on the power sector and said Tenaga Nasional Bhd and YTL Power International Bhd (YTLP) will not be affected by the recent change of government and ongoing policy review exercises.
5347 YTLPF TNABY 6742 TNABF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...